Additionally, a multicenter phase II trial (NCT04736823) evaluated AK112, a novel PD-1/VEGF bispecific antibody, in combination with platinum-based chemotherapy in patients with advanced NSCLC who had progressed on prior PD-1/L1 inhibitors. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.